The effect of eight weeks of rabeprazole therapy on nitric oxide plasma level and esophageal pH and motility and motility nitric oxide plasma level in patients with erosive esophagitis

Medical Science Monitor

Volumn 10, Issue 2, 2004, Pages

  Świa̧tkowski, Maciej ^a   Budzyński, Jacek ^a   Kłopocka, Maria ^a   Grad, Krzysztof ^a   Pulkowski, Grzegorz ^a   Augustyńska, Beata ^a   Suppan, Karol ^a   Fabislak, Jacek ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Erosive esophagitis; Esophageal manometry; Nitric oxide; PH metry

Indexed keywords

NITRIC OXIDE; RABEPRAZOLE;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; ESOPHAGUS BIOPSY; ESOPHAGUS MOTILITY; ESOPHAGUS PH; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; MALE; MANOMETRY; PERISTALSIS; PH MEASUREMENT; REFLUX ESOPHAGITIS; SCORING SYSTEM; SPECTROPHOTOMETRY;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; BENZIMIDAZOLES; ESOPHAGITIS, PEPTIC; ESOPHAGUS; FEMALE; GASTROINTESTINAL MOTILITY; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MANOMETRY; MIDDLE AGED; MONITORING, AMBULATORY; NITRIC OXIDE; NITRITES; OMEPRAZOLE; TIME FACTORS;

EID: 1242308293     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Lundell LR, Dent J, Bennett JR et al: Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut, 1999; 45: 172-80
2. Stendal Ch: Practice guide to gastrointestinal function testing. Oxford: Blackwell Science, 1997
3. Quigley EM: Factors that influence therapeutic outcomes in symptomatic gastroesophageal reflux disease. Am J Gastroenterol, 2003; 98(suppl 3): S24-S30
4. Castell DO, Kahrilas PJ, Richter JE et al: Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol, 2002; 97: 575-83
5. Świa̧tkowski M, Sobczyński L, Budzyński J et al: Zależności miȩdzy wynikami badania endoskopowego i histopatologicznego błony śluzowej przełyku oraz dobowej pH-metrii przełykowej u pacjentów diagnozowanych z powodu nietypowych bólów w klatce piersiowej. Valetudinaria. Postȩpy Medycyny Klinicznej i Wojskowej, 2000; 5: 45-52
6. Janssens JP, Vantrappen G: Irritable esophagus. Am J Med, 1992; 92(suppl 5A): 27S-32S
7. Johnson DA, Winters C, Spurling TJ et al: Esophageal acid sensitivity in Barrett's esophagus. Clin-Gastroenterol, 1987; 9: 23-27
8. Timmer R, Breumelhof R, Nadorp JH, Smout AJ: Esophageal motility in low-grade reflux esophagitis, evaluated by stationary and 24-hour ambulatory manometry. Am J Gastroenterol, 1993; 88: 837-41
9. Burns TW, Venturatos SG: Esophageal motor function and response to acid perfusion in patients with symptomatic reflux esophagitis. Dig Dis Sci, 1985; 30: 529-35
10. Katz PO, Knuff TE, Benjamin SB, Castell DO: Abnormal esophageal pressures in reflux esophagitis: cause or effect? Am J Gastroenterol. 1986; 81: 744-46
11. Adamek RJ, Wegener M, Wienbeck M, Pulte T: Esophageal motility disorders and their coexistence with pathologic acid reflux in patients with noncardiac chest pain. Scand J Gastroenterol, 1995; 30: 833-38
12. Cucchiara S, Minella R, Campanozzi A et al: Effects of omeprazole on mechanisms of gastroesophageal reflux in childhood. Dig Dis Sci, 1997; 42: 293-99
13. Netzer P, Gut A, Brundler R et al: Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis. Aliment Pharmacol Ther, 2001; 15: 1375-84
14. Smythe A, Bird NC, Troy GP et al: Does the addition of a prokinetic to proton pump inhibitor therapy help reduce duodenogastrooesophageal reflux in patients with Barrett's oesophagus? Eur J Gastroenterol Hepatol, 2003; 15: 305-12
15. Wetscher GJ, Profanter C, Gadenstatter M et al: Medical treatment of gastroesophageal reflux disease does not prevent the development of Barrett's metaplasia and poor esophageal body motility. Langenbecks Arch Chir, 1997; 382: 95-99
16. Kassim SK, El Touny M, El Guinaidy M et al: Serum nitrates and vasoactive intestinal peptide in patients with gastroesophageal reflux disease. Clin Biochem, 2002; 35: 641-46
17. Weusten BL, Smout AJ: Primary oesophageal motility disorders: how primary are they? Eur J Gastroenterol Hepatol, 1999; 11: 1345-47
18. Tomita R, Tanjoh K, Fujisaki S, Fukuzawa M: Physiological studies on nitric oxide in the lower esophageal sphincter of patients with reflux esophagitis. Hepatogastroenterology, 2003; 50: 110-14
19. Casselbrant A, Pettersson A, Fandriks L: Oesophageal intraluminal nitric oxide facilitates the acid-induced oesophago-salivary reflex. Scand J Gastroenterol, 2003; 38: 235-38
20. Wen ZH, Gardener E, Wang YP: Nitrates for achalasia. Cochrane Database Syst Rev, 2002; (4): CD002299
21. Bortolotti M, Brunelli F, Sarti P, Miglioli M: Clinical and manometric effects of L-arginine in patients with chest pain and oesophageal motor disorders. Ital J Gastroenterol Hepatol, 1997; 29: 320-24
22. Eherer AJ, Schwetz I, Hammer HF et al: Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders. Gut, 2002; 50: 758-64
23. Kelicen P, Pekiner C, Sarioglu Y, Uma S: Omeprazole-induced relaxation in rat aorta is partly dependent on endothelium. Pharmacol Res, 2002; 46: 321-23
24. Chandranath SI, Bastaki SM, Singh J: A comparative study on the activity of lansoprazole, omeprazole and PD-136450 on acidified ethanol- and indomethacin-induced gastric lesions in the rat. Clin Exp Pharmacol Physiol, 2002; 29: 173-80
25. Watanabe T, Higuchi K, Tominaga K et al: Cytoprotective effect of pantoprazole against ethanol-induced gastric mucosal damage: possible involvement of nitric oxide. Drugs Exp Clin, Res. 2000; 26: 41-45
26. Sugiura T, Iwakiri K, Kotoyori M, Kobayashi M: Relationship between severity of reflux esophagitis according to the Los Angeles classification and esophageal motility. J Gastroenterol, 2001; 36: 226-30